AbbVie Inc. $ABBV Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 95.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 12,000 shares of the company’s stock after selling 256,264 shares during the period. Jefferies Financial Group Inc.’s holdings in AbbVie were worth $3,139,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Burk Holdings LLC acquired a new stake in AbbVie during the second quarter valued at $30,000. Marquette Asset Management LLC grew its stake in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Principia Wealth Advisory LLC grew its stake in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. IMG Wealth Management Inc. increased its position in AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the last quarter. Finally, Tacita Capital Inc acquired a new position in AbbVie in the 2nd quarter worth about $42,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABBV. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Wells Fargo & Company boosted their price target on AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Leerink Partners increased their price objective on AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a report on Monday, November 2nd. Argus raised their price objective on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group lifted their target price on shares of AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Trading Down 0.1%

Shares of NYSE:ABBV opened at $294.75 on Friday. The stock has a market capitalization of $521.01 billion, a PE ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The firm has a fifty day moving average price of $274.82 and a 200 day moving average price of $240.55.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period last year, the company earned $1.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s payout ratio is currently 119.10%.

Recent AbbVie Headlines

Investors following ABBV have been watching these headlines:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.